Product Information
BUPROPION HCL XL 300 MG TABLET is a generic product labeled by Slate Run Pharmaceuticals LLC, priced at $0.1154 per EA under NDC 70436001104. Its NADAC has been published 375 times since Mar 20, 2019.
FDA first approved this application on Jun 14, 2018. Its Orange Book therapeutic-equivalence code is AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Slate Run Pharmaceuticals LLCNDC
70436001104
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
5/20/2026
Active Ingredients
BUPROPION HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA210015FDA Approved
6/14/2018
TE Code
AB3
On Market Since
12/1/2018
Pharmacological Classes
Price Statistics
The NADAC for BUPROPION HCL XL 300 MG TABLET has been published 375 times since Mar 20, 2019, and over the history we have for it it has declined 71.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1154 per EA |
|---|---|
| All-time high | $0.4702 (Sep 11, 2019) |
| All-time low | $0.1033 (Feb 18, 2026) |
| 52-week high | $0.1492 |
| 52-week low | $0.1033 |
| Median price | $0.1780 |
| Average price | $0.1993 |
| Largest weekly change | -33.9% (Sep 18, 2019) |
| Weeks tracked | 375 |
| Tracking since | Mar 20, 2019 |
1W
N/A
1M
N/A
3M
N/A
6M
+11.7%
1Y
-22.2%
3Y
-35.2%
5Y
-44.1%
All
-71.4%
Last surveyed May 20, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 12% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of BUPROPION HCL XL 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUPROPION HCL XL 300 MG TABLET, manufactured by Slate Run Pharmaceuticals LLC, is $0.1154 per EA (NDC 70436001104), effective May 20, 2026.
How has the price of BUPROPION HCL XL 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUPROPION HCL XL 300 MG TABLET has declined 71.4%. It has been tracked across 375 weekly CMS publications since Mar 20, 2019.
What are the highest and lowest recorded NADAC prices for BUPROPION HCL XL 300 MG TABLET?
Since Mar 20, 2019, the NADAC for BUPROPION HCL XL 300 MG TABLET has ranged from a low of $0.1033 (Feb 18, 2026) to a high of $0.4702 (Sep 11, 2019), with a median of $0.1780 per EA.
Are there cheaper alternatives to BUPROPION HCL XL 300 MG TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BUPROPION HCL XL 300 MG TABLET, is $0.1014 per EA — about 12% below BUPROPION HCL XL 300 MG TABLET.
Who manufactures BUPROPION HCL XL 300 MG TABLET?
BUPROPION HCL XL 300 MG TABLET (NDC 70436001104) is labeled by Slate Run Pharmaceuticals LLC, and CMS classifies it as a generic product.